In the ongoing saga of Outcome Health, a judge yesterday denied a request by investors to freeze part of its funding.
Takeda, along with Lundbeck and Advocate Health Care, will study an app to track and measure patients’ experience on antidepressant therapies.
Merck’s drug for chemo-induced nausea and vomiting has some new competition.
Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer's Ibrance. So it’s branching out.
Outcome Health may be fending off lawsuits, allegations, investigations and the media spotlight, but the company still aims to get some work done.
Merck's antiviral business suffered some serious blows this year, but it now boasts a new product: Prevymis, a CMV fighter approved by the FDA on Thursday.
Keryx’s Auryxia has struggled. But with its latest FDA nod, the company’s prepping for a launch that it thinks can boost the drug.
Pfizer has relaunched its “Know Pneumonia” disease awareness campaign with a myths-and-facts approach.
Outcome Health investors sued for fraud Tuesday, weeks after whistleblower allegations threw the company into turmoil.
Roche's Alecensa nabbed a new FDA approval to treat first-line lung cancer, putting it on even footing with Pfizer's Xalkori and Novartis'…